IGF-1 LR3 vs tesamorelin: what the evidence actually says

Last updated 2026-07-24

What is the actual difference between IGF-1 LR3 and tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It doesn't raise growth hormone directly; it stimulates the pituitary gland to release GH, which then triggers the liver to produce IGF-1 as a downstream effect ^{[1] [2]}. It is sold under the brand name Egrifta (and the ready-to-mix version Egrifta SV) and is FDA-approved for one specific indication: reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy ^[1]. IGF-1 LR3 is a different animal entirely. It's a modified, long-acting version of insulin-like growth factor 1 itself, engineered with an amino acid substitution and a 13-amino-acid extension (the "LR3" part) that reduces its binding to IGF-binding proteins, so it circulates longer and hits IGF-1 receptors harder and longer than native IGF-1. It is not an FDA-approved drug. It has no brand name, no phase 3 trial, and no approved indication for anything in humans. It exists almost entirely in the research-chemical and underground bodybuilding markets. The core distinction isn't subtle: one is a regulated pharmaceutical with a defined mechanism, dosing regimen, and outcome data. The other is a lab reagent that people inject off internet orders. A 2026 review of injectable peptide therapy in sports medicine grouped compounds like this among substances physicians are increasingly asked about by athletes, precisely because the evidence and safety profile for many of them remain undefined [see Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians, PMID 41476424].

What clinical evidence supports tesamorelin?

Tesamorelin has two pooled phase 3, multicenter, double-blind, placebo-controlled trials in HIV-infected patients with excess abdominal fat, with safety extension data published in The Journal of Clinical Endocrinology and Metabolism ^[3]. That's the evidence base the FDA approval rests on. Beyond those core trials, tesamorelin has been studied for its effects on visceral adipose tissue and downstream liver health: a trial in The Lancet HIV found effects on non-alcoholic fatty liver disease in HIV patients ^[4], and a study in AIDS found that visceral fat reduction with tesamorelin was associated with improved liver enzymes ^[5]. There's also mechanistic and biomarker work: a 2021 AIDS study found tesamorelin improves fat quality independent of changes in fat quantity ^[6], and a 2020 JCI Insight paper examined hepatic transcriptomic signatures in HIV-associated NAFLD, followed by a 2021 Scientific Reports paper mapping response pathways using proteomic and transcriptomic approaches ^{[7] [8]}. A 2011 AIDS paper looked at inflammatory markers and their relationship to visceral fat reduction ^[9]. More recently, a 2024 study in AIDS examined efficacy and safety specifically in people with HIV on integrase inhibitors, a more modern antiretroviral backbone than the original trials used ^[10], and a 2025 Journal of Infectious Diseases paper studied tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity ^[11]. A 2026 meta-analysis of randomized controlled trials in Obesity Research & Clinical Practice pooled body composition, hepatic fat, and metabolic and safety outcomes across tesamorelin RCTs in HIV-associated lipodystrophy ^[12]. That's a meaningful amount of accumulated trial data for one indication. None of it, worth saying plainly, is evidence for fat loss or anti-aging use in people without HIV-associated lipodystrophy. The FDA approval is narrow. Off-label use happens, but it happens without the same trial support behind it. For a full breakdown of the trial data, see the main tesamorelin evidence page.

What clinical evidence supports IGF-1 LR3?

There isn't any meaningful clinical evidence, and that's the honest answer. IGF-1 LR3 has no published phase 1, phase 2, or phase 3 human trials in the way tesamorelin does. What exists is basic pharmacology characterizing how the modified molecule behaves (its resistance to IGFBP binding, its receptor affinity), not controlled studies of health outcomes, dosing safety, or efficacy for any therapeutic goal. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons on therapeutic peptides noted specific findings around emerging peptide use in orthopaedic contexts, but the peptide literature broadly treats compounds like IGF-1 LR3 as understudied and largely absent from controlled trial registries [see Therapeutic Peptides in Orthopaedics, PMID 41490200]. A 2026 Sports Medicine paper reviewing safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance is explicit about the gap between approved compounds and the much larger, poorly studied category that includes things like IGF-1 LR3 [see Safety and Efficacy of Approved and Unapproved Peptide Therapies, PMID 41966639]. What you're left with for IGF-1 LR3 is anecdote from bodybuilding forums, extrapolation from native IGF-1 physiology, and a handful of animal or in vitro studies on IGF-1 signaling generally. None of that substitutes for controlled human data. If you want a drug with an actual trial record behind it, tesamorelin has one. IGF-1 LR3 does not.

Is IGF-1 LR3 legal to buy or use?

This is where IGF-1 LR3 runs into a wall that tesamorelin doesn't. Tesamorelin is an FDA-approved drug; a doctor can prescribe Egrifta or Egrifta SV, and a licensed pharmacy fills it. That's a normal, legal prescription pathway. IGF-1 LR3 has no FDA approval and is not on the FDA's list of bulk drug substances that compounding pharmacies may legally use. Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can only use bulk substances that appear on FDA's 503A bulks list or meet narrow exceptions [21 U.S.C. 353a, 13]. The current FDA bulk drug substances list for 503A compounding does not include IGF-1 LR3 ^[13], and it isn't on the separate 503B outsourcing facility bulks list either ^[14]. Practically, that means no legitimate compounding pharmacy can legally prepare IGF-1 LR3 as a compounded drug for patient use in the US. What's sold as "IGF-1 LR3" online is typically labeled "research use only," which is a legal fig leaf, not a safety certification. There's no chain of custody, no verified purity testing standard, and no FDA oversight of what's actually in the vial. Tesamorelin, by contrast, is manufactured under FDA drug manufacturing standards and listed in Drugs@FDA, the FDA's own database of approved drug products ^[15]. That's a real, checkable regulatory record. IGF-1 LR3 has nothing equivalent.

How do the mechanisms differ, and does that matter for safety?

Tesamorelin works upstream. It stimulates the pituitary to release GH, and the body's own feedback loops (somatostatin, IGF-1 negative feedback) still operate somewhat normally on top of that stimulation ^{[16] [1]}. That physiological braking system is part of why GHRH analogues have a different safety profile than directly dosing GH or IGF-1 themselves. IGF-1 LR3 skips the pituitary and the feedback loop almost entirely. It's a modified IGF-1 molecule engineered specifically to resist binding by IGF-binding proteins, which under normal physiology regulate how much free, active IGF-1 reaches tissue. Bypass those binding proteins and you get a molecule that binds IGF-1 receptors more aggressively and for longer than the body ever intends. IGF-1 receptor signaling is also insulin-receptor-adjacent and implicated in cell growth and proliferation pathways, which is exactly why unregulated, high-affinity IGF-1 receptor agonists raise real theoretical concern around abnormal cell growth signaling. This isn't a proven cancer risk in humans (there's no trial data either way for IGF-1 LR3 specifically) but it is a legitimate, mechanism-based reason for caution that reviewers flag when discussing unapproved peptides in sports medicine and orthopaedic contexts [see Injectable Peptide Therapy, PMID 41476424; Safety and Efficacy of Approved and Unapproved Peptide Therapies, PMID 41966639]. A 2013 review on growth hormone in the aging male discusses how GH/IGF-1 axis manipulation carries known tradeoffs even in well-studied contexts, underlining why direct IGF-1 receptor agonism deserves more caution, not less ^[16].

How does dosing and administration compare?

Tesamorelin has an established, FDA-labeled dosing regimen: 2 mg administered by subcutaneous injection once daily, reconstituted from lyophilized powder before use. Population pharmacokinetic modeling in HIV-infected patients and healthy subjects has characterized its absorption and clearance in real detail ^[17], which is the kind of data that lets clinicians and pharmacists set a dose with actual confidence. IGF-1 LR3 has no FDA label, no standardized dose, and no population pharmacokinetic study in humans that would tell you how it clears or accumulates. Dosing information circulating online for IGF-1 LR3 comes from user forums and anecdotal bodybuilding protocols, not from regulatory-grade trials. That's a meaningful gap when you're talking about a molecule with a long half-life (that's the whole point of the LR3 modification) and receptor-level effects on tissue growth. If you're looking at tesamorelin specifically, the tesamorelin dosage page and the tesamorelin dosage calculator walk through the labeled regimen and reconstitution steps in detail, and the tesamorelin reconstitution guide covers mixing the lyophilized powder correctly. There's no equivalent reliable resource for IGF-1 LR3 because there's no equivalent reliable dosing data.

Which one actually reduces visceral fat, and by how much?

Tesamorelin's visceral fat effect is the best-documented part of its profile. The pooled phase 3 trial data in HIV patients with excess abdominal fat showed measurable reductions in visceral adipose tissue on top of placebo, with the safety extension data published alongside it ^[3]. Follow-on work has connected that visceral fat reduction to downstream liver benefits, including improved liver enzymes ^[5] and effects on non-alcoholic fatty liver disease ^[4]. A 2023 post hoc analysis in the Journal of Clinical and Translational Science even looked at whether the presence or absence of dorsocervical fat pads changed the treatment response ^[18]. IGF-1 LR3 has no controlled trial measuring visceral fat change in humans at all. Claims about it reducing fat or building lean mass come from anabolic mechanism extrapolation (IGF-1 signaling does promote protein synthesis and can influence fat and muscle metabolism in general physiology) and from anecdote, not from a single published RCT on IGF-1 LR3 itself. Here's the comparison stripped down: | Factor | Tesamorelin (Egrifta/Egrifta SV) | IGF-1 LR3 |

Are there safety data for either compound?

Tesamorelin's safety profile comes from the phase 3 trials and their extension phases, plus a growing body of secondary analyses. Reported adverse effects in the trials include injection site reactions, joint pain (arthralgia), and effects on glucose metabolism that warrant monitoring in at-risk patients; the full label discusses these based on the core trial data ^{[3] [1]}. A meta-analysis pooling RCT safety outcomes gives a more consolidated picture across multiple trials rather than relying on any single study ^[12]. That's not a small amount of scrutiny for a peptide drug. IGF-1 LR3 safety data in humans, by contrast, is essentially absent from the peer-reviewed literature. What's written about IGF-1 LR3 safety concerns is largely mechanism-based reasoning drawn from general IGF-1 receptor biology, not trial-derived adverse event rates. Reviews covering unapproved peptides used in sports and orthopaedic settings consistently flag this as the central problem: physicians are being asked about compounds for which no systematic safety monitoring has ever occurred [see Injectable Peptide Therapy, PMID 41476424; Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions, PMID 42123471]. For tesamorelin specifically, the tesamorelin peptide side effects page covers what the trials documented in more detail. There's no equivalent page possible for IGF-1 LR3, because there's no equivalent trial-derived side effect data to report.

Can either be detected in anti-doping testing?

Yes, and this matters if you're a competitive athlete. GHRH analogues and IGF-1 axis manipulators are both banned under most anti-doping codes, and detection science has kept pace. A 2021 paper in Drug Testing and Analysis specifically covers advances in detecting GHRH synthetic analogs, which would include tesamorelin's drug class ^[19]. IGF-1 LR3, as a modified IGF-1 molecule with a synthetic amino acid extension, is likewise a detectable target for anti-doping labs looking for exogenous IGF-1 axis manipulation, given it doesn't match the structure of endogenous human IGF-1. The practical upshot: neither compound is a quiet way to boost GH/IGF-1 signaling in a tested sport. Tesamorelin's legitimate medical use in HIV lipodystrophy doesn't create a loophole for athletes, and IGF-1 LR3's underground status doesn't make it undetectable.

So which one should you actually consider?

If you have HIV-associated lipodystrophy with excess visceral abdominal fat, tesamorelin is the option with an FDA approval, a defined dosing regimen, phase 3 trial data, and a prescription pathway through a licensed provider ^{[1] [3]}. That's not a marginal advantage. It's the difference between a regulated drug and an unregulated research chemical. If you're looking at either compound for general fat loss, muscle gain, or anti-aging purposes outside the approved indication, be clear-eyed about what you're doing: that's off-label use for tesamorelin, and it's use of an unapproved substance with no human trial record at all for IGF-1 LR3. The gap in evidence, legal status, and safety monitoring between the two isn't close. Tesamorelin Co covers the provider-reviewed pathway for tesamorelin: a licensed prescriber evaluates you, and prescriptions are filled through a legitimate pharmacy partner rather than an unregulated online seller. That route at least puts you inside the same regulatory system the phase 3 trials were built on. IGF-1 LR3 doesn't have an equivalent legitimate pathway to point you toward, because none currently exists in the US regulatory framework.

Frequently asked questions

Is IGF-1 LR3 the same thing as tesamorelin?

No. Tesamorelin is a GHRH analogue that stimulates the pituitary to release growth hormone, which then raises IGF-1 indirectly. IGF-1 LR3 is a modified form of IGF-1 itself that acts directly on IGF-1 receptors, bypassing the pituitary and the body's normal feedback controls. They work at different points in the same hormonal axis and are not interchangeable.

Does IGF-1 LR3 have FDA approval?

No. IGF-1 LR3 has no FDA-approved product, no brand name, and no approved indication for any use in humans. Tesamorelin is FDA-approved as Egrifta and Egrifta SV specifically for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Anything sold as IGF-1 LR3 online is typically labeled research-use-only, which carries no safety or quality guarantee.

Can a compounding pharmacy legally make IGF-1 LR3?

Not legitimately. Under 21 U.S.C. 353a, compounding pharmacies may only use bulk substances on FDA's approved 503A bulks list, and IGF-1 LR3 does not appear on that list or on the separate 503B outsourcing facility list. Legal compounding pathways exist for many FDA-regulated drugs but not currently for IGF-1 LR3.

Which has better evidence for visceral fat loss, IGF-1 LR3 or tesamorelin?

Tesamorelin, by a wide margin. It has pooled phase 3, double-blind, placebo-controlled trial data showing measurable visceral fat reduction in HIV-associated lipodystrophy, plus follow-on studies linking that fat loss to liver enzyme improvement. IGF-1 LR3 has no published controlled human trial measuring visceral fat change at all.

Is IGF-1 LR3 more dangerous than tesamorelin?

It's not proven to be more dangerous in a clinical trial sense, because it hasn't been studied in controlled human trials the way tesamorelin has. What raises concern is mechanism: IGF-1 LR3 resists normal IGF binding protein regulation and drives stronger, longer IGF-1 receptor signaling, which is theoretically linked to abnormal cell growth pathways. Tesamorelin's safety profile is documented from actual trial data; IGF-1 LR3's is not documented at all.

What is tesamorelin actually approved for?

Tesamorelin (Egrifta, Egrifta SV) is FDA-approved for reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, bodybuilding, or anti-aging use. Any use outside that specific indication is off-label, meaning a prescriber can choose to prescribe it but it lacks the same trial support for that purpose.

Can athletes use either compound without risking a doping violation?

No. Both GHRH analogues like tesamorelin and modified IGF-1 molecules like IGF-1 LR3 fall under classes banned by most anti-doping codes, and detection methods for GHRH synthetic analogs have specifically advanced in recent years. Neither compound offers a safe or undetectable route around doping tests.

How is tesamorelin dosed compared to IGF-1 LR3?

Tesamorelin has an FDA-labeled dose of 2 mg subcutaneously once daily, with population pharmacokinetic data supporting that regimen in both HIV-infected patients and healthy subjects. IGF-1 LR3 has no standardized, regulatory-reviewed human dose; any dosing protocol circulating online comes from anecdote, not trial data.

Does tesamorelin help with liver fat, more than visceral fat?

Yes, there's specific trial evidence for this. A randomized, double-blind, multicenter trial published in The Lancet HIV studied tesamorelin's effects on non-alcoholic fatty liver disease in people with HIV, and a separate AIDS study linked tesamorelin-driven visceral fat reduction to improved liver enzymes. This is trial-supported, not anecdotal.

Why do bodybuilders use IGF-1 LR3 if it has no trial data?

The appeal is mechanistic extrapolation: IGF-1 signaling generally supports protein synthesis and tissue growth, and LR3's resistance to binding proteins theoretically means stronger, longer receptor activation. That reasoning isn't backed by controlled human trials on IGF-1 LR3 itself, though, so any perceived benefit or risk profile is based on anecdote and physiology inference, not evidence.

Is tesamorelin available as a legitimate prescription?

Yes. Because tesamorelin is FDA-approved, a licensed prescriber can evaluate a patient and write a prescription filled through a legitimate pharmacy, following the approved label for HIV-associated lipodystrophy or prescribing off-label at clinical discretion. This is a fundamentally different, legally recognized pathway compared to buying IGF-1 LR3 as an unregulated research chemical online.

Has tesamorelin been studied in patients on modern HIV medications?

Yes. A 2024 study published in AIDS specifically examined the efficacy and safety of tesamorelin in people with HIV taking integrase inhibitors, a newer class of antiretroviral drugs than what was used in the original core trials, adding more contemporary trial evidence to the existing dataset.

Sources

1. PubMed, Tesamorelin (Nature Reviews Drug Discovery, 2011): Tesamorelin is a GHRH analogue that stimulates pituitary GH release and is FDA-approved for HIV-associated lipodystrophy-related visceral fat reduction.
2. PubMed, Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009): Tesamorelin acts as a GHRH analogue upstream of the GH/IGF-1 axis rather than acting directly on IGF-1 receptors.
3. PubMed, Effects of tesamorelin (TH9507) pooled phase 3 trial analysis (J Clin Endocrinol Metab, 2010): Pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data forms the basis of tesamorelin's approval evidence.
4. PubMed, Effects of tesamorelin on NAFLD in HIV (The Lancet HIV, 2019): A randomized, double-blind, multicenter trial studied tesamorelin's effects on non-alcoholic fatty liver disease in HIV patients.
5. PubMed, Visceral fat reduction with tesamorelin associated with improved liver enzymes (AIDS, 2017): Visceral fat reduction from tesamorelin was associated with improved liver enzymes in HIV patients.
6. PubMed, Tesamorelin improves fat quality independent of fat quantity (AIDS, 2021): Tesamorelin improves fat quality independent of changes in fat quantity.
7. PubMed, Effects of tesamorelin on hepatic transcriptomic signatures (JCI Insight, 2020): Tesamorelin's effects on hepatic transcriptomic signatures were studied in HIV-associated NAFLD.
8. PubMed, Delineating tesamorelin response pathways (Scientific Reports, 2021): Proteomic and transcriptomic approaches mapped tesamorelin response pathways in HIV-associated NAFLD.
9. PubMed, Effects of tesamorelin on inflammatory markers (AIDS, 2011): Tesamorelin's effect on inflammatory markers was studied in relation to visceral adipose reduction.
10. PubMed, Efficacy and safety of tesamorelin on integrase inhibitors (AIDS, 2024): Tesamorelin efficacy and safety was studied specifically in people with HIV taking integrase inhibitors.
11. PubMed, Effects of Tesamorelin on Neurocognitive Impairment (J Infect Dis, 2025): Tesamorelin's effects on neurocognitive impairment were studied in people with HIV and abdominal obesity.
12. PubMed, Body composition, hepatic fat, metabolic and safety outcomes meta-analysis (Obesity Research & Clinical Practice, 2026): A meta-analysis pooled body composition, hepatic fat, metabolic, and safety outcomes across tesamorelin RCTs.
13. Cornell Law, 21 U.S.C. 353a, pharmacy compounding: Compounding pharmacies are legally restricted to bulk substances on FDA's approved lists under section 503A.
14. FDA, bulk drug substances used in compounding under section 503A: FDA maintains the 503A bulks list of substances legally permitted for compounding, which does not include IGF-1 LR3.
15. eCFR, 21 CFR 216.24, the 503B Bulks List: IGF-1 LR3 does not appear on the separate 503B outsourcing facility bulks list either.
16. FDA, Drugs@FDA approved drug products database: Tesamorelin (Egrifta/Egrifta SV) is listed as an FDA-approved drug product in the Drugs@FDA database.
17. PubMed, Growth hormone in the aging male (Best Pract Res Clin Endocrinol Metab, 2013): GH/IGF-1 axis manipulation carries physiological tradeoffs discussed in reviews of growth hormone therapy.
18. PubMed, Population pharmacokinetic analysis of tesamorelin (Clin Pharmacokinet, 2015): Population pharmacokinetic modeling has characterized tesamorelin absorption and clearance in HIV-infected patients and healthy subjects.
19. PubMed, Effect of tesamorelin with/without dorsocervical fat, post hoc analysis (J Clin Transl Sci, 2023): A post hoc analysis of the phase 3 trial examined whether dorsocervical fat presence altered tesamorelin treatment response.
20. PubMed, Advances in detection of GHRH synthetic analogs (Drug Test Anal, 2021): Detection science for GHRH synthetic analogs like tesamorelin has specifically advanced, relevant to anti-doping testing.